In Taiwan, only one drug in this class (moclobemide
) is approved.
[1, 27, 76, 78] In a prospective study carried out in Turkey investigating the efficacy and tolerability of moclobemide
therapy in 21 FM patients, there was no significant improvement in symptoms other than pain and it was concluded that moclobemide
could be used in patients with FM who had severe depression.
Additionally, MAO inhibitors, such as clorgiline, phenelzine, moclobemide
and tranylcypromine, which are used to treat depression, and anticholinergics, such as scopolamine, biperidene, trihexyphenydil and benztropine, have some serious potential to increase mood and physical resistance, very similar to amphetamines.
Stefanis, "Clinical, endocrine and neurochemical effects of moclobemide
in depressed patients," Acta Psychiatrica Scandinavica, vol.
The reagents used in the enzymatic assay including Ampliflu[TM] Red (10-acetyl-3,7-dihydroxyphenoxazine), peroxidase from horseradish, hMAO-A, hMAO-B, [H.sub.2][O.sub.2], tyramine hydrochloride, selegiline, and moclobemide
were purchased from Sigma-Aldrich (Steinheim, Germany).
The first molecule with these properties was moclobemide
, which, nevertheless, did not have the expected clinical success.
Standards of moclobemide
and selegiline are used as positive controls for MAO-A and MAO-B inhibition, respectively.
MAO inhibitors including tranylcypromine, isocarboxazid, phenelzine, and moclobemide
are often used as first-line therapy .
In recent years, the MAOI has been represented by moclobemide
, which selectively reversibly inhibits type A MAO and has been attracting attention again due to its side effects.
The patient had been administered different medication regimens for the last 3 years and lamotrigine 100 mg/day and moclobemide
600 mg/day for the last 1.5 years.
Moreover, the novel selective and reversible MAOI (such as moclobemide
) are reported to be both well-tolerated compounds and free from the above-mentioned interaction included in the elderly .
In terms of active principle, amitriptyline (34.7%) and imipramine (13.9%) were the most used among the TCAs, fluoxetine among SSRIs (18.1%) and moclobemide
among the MAOIs (5.1%).